SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

SPY230

SYRE·Spyre Therapeutics, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
If Part B data are positive in 2027, a Phase 3 program would follow, meaning potential approval is likely several years away (2029 or later), assuming successful trials.
Why 6/10
SPY230 has no PDUFA date (still Phase 2). The next hard catalyst is the SKYLINE Part B induction data readout, expected in Q3 2027 (roughly 10 months away). SPY230 is one of three combination arms in Part B, and the combination strategy is central to Spyre's thesis, but the company also has other pipeline programs (SPY120, SPY130, SPY772), so the score reflects a major but not single-asset binary event.
Actionable Insight NEUTRAL

The next major catalyst for SPY230 is the SKYLINE Part B induction data readout, expected in Q3 2027 (roughly 10 months away). Positive data showing superiority of the SPY230 combination over its constituent monotherapies would validate Spyre's combination strategy and likely drive the stock higher. Negative or equivocal data would undermine the central thesis and could trigger significant downside given the premium valuation.

Price Chart

Loading chart...

Executive Summary

SPY230 is a Phase 2 combination antibody therapy from Spyre Therapeutics (NASDAQ: SYRE) that pairs an anti-TL1A antibody (SPY002) with an anti-IL-23 antibody (SPY003) for inflammatory bowel disease. All three monotherapy components achieved positive proof-of-concept in Part A of the SKYLINE trial. The combination arms (SPY120, SPY130, and SPY230) are now enrolling in Part B, with induction data expected in Q3 2027. Spyre has a strong cash position ($1.47B pro forma) and broad institutional support, but faces intense competition in the TL1A space from Merck (Phase 3), Roche, and others. The stock trades near $99 with a Strong Buy analyst consensus and a mean price target of $122.53.

How It Works

SPY230 is a combination of two engineered antibodies given together as a single injection. One antibody (SPY002) blocks TL1A, a protein that drives inflammation and tissue scarring in the gut. The other (SPY003) blocks IL-23, another inflammatory signal. By hitting both targets at once, the drug aims to shut down inflammatory bowel disease (IBD) more completely than blocking either pathway alone. The antibodies are engineered to last longer in the body (extended half-life), potentially allowing patients to receive injections only once every 3 to 6 months instead of every few weeks.

Trial Status

SPY230 is being evaluated in Part B of the Phase 2 SKYLINE-UC platform trial (NCT07012395) in moderate-to-severe ulcerative colitis. Part A (open-label monotherapy proof-of-concept) completed with positive data for all three component antibodies. Part B is actively enrolling and will test SPY120, SPY130, and SPY230 combinations at high doses versus monotherapies and placebo using a factorial design. The company reported that Part B enrollment is ahead of schedule.

The Two-Sided Case

▲ Bull Case5
All three monotherapy components of SPY230 (SPY001, SPY002, SPY003) achieved positive proof-of-concept in Part A of the SKYLINE trial, validating the biological rationale for the combination approach.
Preclinical data showed that combined TL1A and IL-23 inhibition produced additive efficacy over either monotherapy alone, and the extended half-life (~85 days for SPY003) supports potential quarterly or twice-annual dosing, a significant convenience advantage.
Analyst consensus is Strong Buy (21 buy/strong buy, 2 hold, 0 sell) with a mean price target of $122.53, implying ~23.4% upside from the Nov 4 close of $99.04.
Major institutional investors accumulated heavily in Q2 2026: FMR LLC ($1.16B position), BlackRock ($578M), and T. Rowe Price (added 85%, now $263M). Pro forma cash of $1.47B funds operations into 2H 2029.
The SKYLINE platform study design allows data sharing across arms, potentially enabling efficient Phase 3 dose regimen optimization and a faster path to registration if Part B data are positive.
▼ Bear Case5
SPY230 is still in Phase 2 with no approved products or revenue; the company posted a $96.1M net loss in Q3 2026 and burned $77.5M in operating cash flow in the quarter.
The October 2026 $350M stock offering at $85/share (an 8.8% discount) diluted existing shareholders by roughly 4.1 million shares, and ongoing ATM sales add further dilution risk.
The TL1A target space is intensely competitive: Merck (tulisokibart) is already in Phase 3, and multiple bispecific programs (Roche, XmAb, ALX001) are in development, raising the bar for SPY230 to differentiate.
Insider selling in Q4 2026 (CEO Turtle Cameron and other executives sold shares under 10b5-1 plans) and elevated short-sale volume (66.2% of off-exchange volume on Nov 4, 2026) suggest mixed sentiment among those closest to the business.
SPY072, another TL1A asset, failed primary endpoints in PsA and axSpA, raising questions about the breadth of the TL1A mechanism beyond IBD.

Upcoming Catalysts

  • SKYLINE Part B induction data readout for SPY120, SPY130, and SPY230 combinations, expected in Q3 2027
  • SKYLIGHT Phase 2 trial in hidradenitis suppurativa (SPY772), topline data expected late 2027 or early 2028
  • Potential partnership or licensing interest given the competitive TL1A/IL-23 landscape

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report

Sources · 13

Hover a chip for the title
1 spyre.com2 ir.spyre.com3 markets.financialcontent.com4 clinicaltrials.gov5 academic.oup.com6 academic.oup.com7 ir.spyre.com8 fiercebiotech.com9 fiercebiotech.com10 adisinsight.springer.com11 biospace.com12 sec.gov13 sec.gov